Before the introduction of anti-vascular endothelial growth factors (anti-VEGF), the goal of treatment in neovascular age-related macular degeneration (nAMD) was only to prevent vision loss.1,2,3,4,5,6,7 The first labeled intravitreal drug for the treatment of nAMD was pegaptanib, then off-label drug bevacizumab and approved drugs aflibercept and ranibizumab have led us to prevention of vision loss in most of the nAMD patients and vision gain in one third of them.4,5,6,7,8 Several treatment regimens were evaluated in randomized controlled trials for each drug. This evidence concerns the gene VEGFA and wet macular degeneration.